Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.

被引：0
|
作者：
O'Shaughnessy, Joyce
Woeckel, Achim
Pistilli, Barbara
Hegg, Roberto
Vahdat, Linda T.
Vuina, Dragica
Asad, Zvk Parisa
Smith, Timothy W.
Kim, Julia
Krop, Ian
机构：
[1] Baylor Univ Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Univ Wurzburg, Wurzburg, Germany
[3] Inst Macerata, Macerata, Italy
[4] Univ Sao Paulo, Sao Paulo, SP, Brazil
[5] Dartmouth Canc Ctr, Lebanon, NH USA
[6] Novartis Oncol, Zagreb, Croatia
[7] Novartis Oncol, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Genesis Res, Hoboken, NY USA
[10] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer
    Goyal, Ravi K.
    Zhang, Jingchuan
    Davis, Keith L.
    Sluga-O'Callaghan, Martina
    Kaufman, Peter A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 205 (01) : 201 - 210
  • [42] Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer
    Ravi K. Goyal
    Jingchuan Zhang
    Keith L. Davis
    Martina Sluga-O’Callaghan
    Peter A. Kaufman
    Breast Cancer Research and Treatment, 2024, 205 : 201 - 210
  • [43] Exploratory analysis of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER-2) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) plus FUL but not TAS plus FUL in SANDPIPER
    Johnson, Radia M.
    Liu, Bonnie
    Cortes, Javier
    Dent, Susan
    Harbeck, Nadia
    Krop, Ian E.
    Jacot, William
    Yauch, Robert L.
    Stout, Thomas J.
    Schimmoller, Frauke
    Gendreau, Steven
    Wilson, Timothy R.
    CANCER RESEARCH, 2023, 83 (07)
  • [44] Clinical outcomes in patients receiving palbociclib plus fulvestrant as first line treatment for ABC/MBC in real world settings in the United States.
    Waller, John
    Mitra, Debanjali
    Taylor-Stokes, Gavin
    Gibson, Katie
    Milligan, Gary
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Real-world (rw) treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC): Insights from The US Oncology Network electronic health record (EHR)
    Bupathi, Manojkumar
    Sura, Sneha
    Ike, Chiemeka
    Morris, Valerie A.
    Conkling, Paul R.
    Todoroff, Karen
    Bhanegaonkar, Abhijeet
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Treatment of elderly patients (pts; > 75 years) with 1st line ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) or endocrine monotherapy (ET) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
    Decker, T.
    Brucker, C.
    Engel, A.
    Fasching, P. A.
    Goehler, T.
    Jackisch, C.
    Janssen, J.
    Koehler, A.
    Luedtke-Heckenkamp, K.
    Lueftner, D.
    van Mackelenbergh, M.
    Marme, F.
    Nusch, A.
    Rautenberg, B.
    Reimer, T.
    Schmidt, M.
    Weide, R.
    Wimberger, P.
    Figueroa, Maslanka S.
    Roos, C.
    Woeckel, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 168 - 169
  • [47] Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study
    Yang, Jin
    Yang, Jiao
    Wang, Guangxi
    Zhang, Haochen
    Zhao, Shidi
    Zhao, Xiaoai
    Dong, Danfeng
    Wang, Le
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
    Bilen, M. A.
    Xi, A. D.
    Wong, A.
    Schroeder, A.
    Kim, R.
    Liu, F. X.
    Peng, J.
    Robinson, S.
    Bhanegaonkar, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
  • [49] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Jerusalem, Guy Heinrich Maria
    De laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    de la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Wang, Craig
    Deore, Uday
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Taran, Tetiana
    Fasching, Peter A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Comparative effectiveness of ribociclib plus fulvestrant (RIB plus FUL) versus palbociclib plus letrozole (PAL plus LET) as first-line (1L) treatment (Tx) of HR+/HER2L advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
    Fasching, P. A.
    Delea, T.
    Lu, Y-S.
    DeBoer, R.
    Hurvitz, S. A.
    Moynahan, A.
    Chandiwana, D.
    Lanoue, B.
    Hu, H.
    Thuerigen, A.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S377 - S378
12345